Effect of Tapioca-based FiberSMART® Compared to a Glucose Challenge or Water Control on Postprandial Glycemia in Healthy Subjects: An Acute Randomized Controlled Trial

Launched by INQUIS CLINICAL RESEARCH · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of dietary fiber called FiberSMART®, made from tapioca, to see how it affects blood sugar levels after eating. Researchers want to find out if FiberSMART® causes a rise in blood sugar similar to what you’d expect from fiber in your diet, and whether this rise is different from what happens after drinking a sugary solution (dextrose) or just water. The goal is to understand if FiberSMART® can be a healthy option that doesn’t spike blood sugar like sugar does.

Healthy adults who are at least 18 years old and able to work in Canada may be eligible to join, as long as they don’t have diabetes, food allergies related to the product, or certain medical conditions or medications that affect blood sugar. Participants will visit the clinic on three separate mornings after fasting overnight. Each time, they will drink either FiberSMART®, a sugary drink, or water, and then have their blood sugar tested through finger-prick blood samples several times over two hours. This helps the researchers see how each drink affects blood sugar levels. The study is currently recruiting people who want to help learn more about this new fiber product.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects are healthy adult males and non-pregnant females. Subjects must be eligible to receive income in Canada. Family members of staff and/or staff that have no responsibilities/tasks on this particular trial may be subjects
• Exclusion Criteria:
• • age less than 18 years;
• • any known food allergies or intolerances to the investigational product;
• • medications known to affect glucose tolerance -but stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable;
• • known history of diabetes mellitus or the use of anti-hyperglycemic drugs or insulin to treat diabetes and related conditions;
• • any major medical or surgical events requiring hospitalization within the preceding 3 months;
• • the presence of disease or drug(s) which influence digestion and absorption of nutrients;
• • the short-term use of systemic steroids or atypical antipsychotics (\<4 weeks) (all of which have major effects on glucose and metabolism and body fat distribution)
• • any other medications or conditions which might, in the opinion of the Medical Director of INQUIS Clinical Research Ltd. (INQUIS), either 1) make participation dangerous to the subject or to others, or 2) affect the results;
• • any subject who cannot or will not comply with the experimental procedures or do not follow INQUIS safety guidelines.